Skip to main content
Journal cover image

Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.

Publication ,  Journal Article
Levy, WC; Hellkamp, AS; Mark, DB; Poole, JE; Shadman, R; Dardas, TF; Anderson, J; Johnson, G; Fishbein, DP; Lee, KL; Linker, DT; Bardy, GH
Published in: JACC Clin Electrophysiol
August 2018

OBJECTIVES: The authors previously developed the Seattle Proportional Risk Model (SPRM) in systolic heart failure patients without implantable cardioverter-defibrillators (ICDs)to predict the proportion of deaths that were sudden. They subsequently validated the SPRM in 2 observational ICD data sets. The objectives in the present study were to determine whether this validated model could improve identification of clinically important variations in the expected magnitude of ICD survival benefit by using a pivotal randomized trial of primary prevention ICD therapy. BACKGROUND: Recent data show that <50% of nominally eligible subjects receive guideline- recommended primary prevention ICDs. METHODS: In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), a placebo-controlled ICD trial in 2,521 patients with an ejection fraction ≤35% and symptomatic heart failure, we tested the use of patient-level SPRM-predicted probability of sudden death (relative to that of non-sudden death) as a summary measurement of the potential for ICD benefit. A Cox proportional hazards model was used to estimate variations in the relationship between patient-level SPRM predictions and ICD benefit. RESULTS: Relative to use of mortality predictions with the Seattle Heart Failure Model, the SPRM was much better at partitioning treatment benefit from ICD therapy (effect size was 2- to 3.6-fold larger for the ICD×SPRM interaction). ICD benefit varied significantly across SPRM-predicted risk quartiles: for all-cause mortality, a +10% increase with ICD therapy in the first quartile (highest risk of death, lowest proportion of sudden death) to a decrease of 66% in the fourth quartile (lowest risk of death, highest proportion of sudden death; p = 0.0013); for sudden death mortality, a 19% reduction in SPRM quartile 1 to 95% reduction in SPRM quartile 4 (p < 0.0001). CONCLUSIONS: In symptomatic systolic heart failure patients with a Class I recommendation for primary prevention ICD therapy, the SPRM offers a useful patient-centric tool for guiding shared decision making.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Clin Electrophysiol

DOI

EISSN

2405-5018

Publication Date

August 2018

Volume

4

Issue

8

Start / End Page

1089 / 1102

Location

United States

Related Subject Headings

  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Practice Guidelines as Topic
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
  • Female
  • Defibrillators, Implantable
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levy, W. C., Hellkamp, A. S., Mark, D. B., Poole, J. E., Shadman, R., Dardas, T. F., … Bardy, G. H. (2018). Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC Clin Electrophysiol, 4(8), 1089–1102. https://doi.org/10.1016/j.jacep.2018.04.015
Levy, Wayne C., Anne S. Hellkamp, Daniel B. Mark, Jeanne E. Poole, Ramin Shadman, Todd F. Dardas, Jill Anderson, et al. “Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.JACC Clin Electrophysiol 4, no. 8 (August 2018): 1089–1102. https://doi.org/10.1016/j.jacep.2018.04.015.
Levy WC, Hellkamp AS, Mark DB, Poole JE, Shadman R, Dardas TF, et al. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC Clin Electrophysiol. 2018 Aug;4(8):1089–102.
Levy, Wayne C., et al. “Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.JACC Clin Electrophysiol, vol. 4, no. 8, Aug. 2018, pp. 1089–102. Pubmed, doi:10.1016/j.jacep.2018.04.015.
Levy WC, Hellkamp AS, Mark DB, Poole JE, Shadman R, Dardas TF, Anderson J, Johnson G, Fishbein DP, Lee KL, Linker DT, Bardy GH. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC Clin Electrophysiol. 2018 Aug;4(8):1089–1102.
Journal cover image

Published In

JACC Clin Electrophysiol

DOI

EISSN

2405-5018

Publication Date

August 2018

Volume

4

Issue

8

Start / End Page

1089 / 1102

Location

United States

Related Subject Headings

  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Practice Guidelines as Topic
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
  • Female
  • Defibrillators, Implantable